Our previous studies showed that single nucleotide polymorphism arrays (SNP-As), applied as a karyotyping platform, complement traditional metaphase cytogenetics (MCs) and improve the diagnostic yield of cytogenetic studies, as SNP-A can more precisely resolve smaller genetic defects and allow for detection of copy number-neutral loss of heterozygosity (CN-LOH), a defect frequently found in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Like balanced translocations, CN-LOH represents a chromosomal abnormality that occurs without a concurrent change in gene copy number. CN-LOH is an increasingly recognized chromosomal mechanism by which homozygous somatic mutations may be acquired during evolution of hematological malignancies and can pinpoint the location of such gene(s); examples include CEBPA, FLT3, WT1, RUNX1, JAK2 and NF1.
1
Deletions involving the short arm of chromosome 17, detectable by MC in MDS and AML, may be associated with a complex karyotype that includes -5/5q-and/or -7/7q-; such patients have a poor prognosis.
2 The well-known tumor suppressor gene TP53, located at 17p13.1, is a likely candidate gene contributing to the disease phenotype after mutation of one or both alleles. Mutations may be linked to loss of 17p by chromosomal or submicroscopic deletion LOH (mut/-) or may occur in the absence of 17p loss in either heterozygous (wt/mut), biallelic (mut1/mut2) or homozygous (mut1/mut1) forms through CN-LOH. Although mutations in TP53 are frequent in solid tumors, the mutation frequency reported in hematological malignancies is much lower. 2 We have applied high-density Affymetrix 250K and 6.0 SNP-A (Affymetrix, Santa Clara, CA, USA) to identify LOH of chromosome 17 in a large cohort of patients (N ¼ 379) with MDS, MDS/MPN and primary and secondary AML. We noted that advanced forms of MDS and AML often harbored areas of LOH (deletion and CN-LOH) involving the short arm of chromosome 17 (Supplementary Tables 1 and 2 ).
In total, we identified 21 (5.5%) patients with LOH17p on chromosome 17. Deletions (-17/17p-) were found in 14 (3.7%) and somatic CN-LOH17p in 7 (1.8%) patients by SNP-A. We defined a commonly deleted region (CDR) on chromosome 17p (Figure 1a) . The CDR at 17p13.1 (6 828 482-8 075 871 bp; 1.25 Mb) contained TP53, among others genes, and was present in 12 of 14 patients with del(17p). In two patients, del(17p) did not span the TP53 locus, suggesting that other genes located in these regions, such as CRK or HIC1, may be involved in disease pathogenesis. Somatic CN-LOH17p was detected in seven patients. The average size of CN-LOH17p detected by SNP-A was 12.1 ± 5.5 Mb. The somatic origin of CN-LOH17p was confirmed by analysis of a control cohort consisting of 1003 individuals, which did not reveal any cases of CN-LOH involving 17p, suggesting that large subtelomeric CN-LOH17p represents an acquired lesion. In addition, SNP-A was performed on paired CD3 þ cells for exemplary cases of del(17p) and CN-LOH17p to confirm the somatic nature of these lesions (Figure 1b) .
Comparison of the clinical characteristic of 21 patients with LOH17p revealed that these patients shared similar features, including a complex karyotype and a strong association between LOH17p and abnormalities of chromosomes 5 and/or 7. In addition, the majority of the 21 patients with LOH17p by SNP-A had aggressive histomorphological features (10 secondary AML, 2 primary AML, 1 t-AML, 1 RAEB-1, 3 RAEB-2, 3 RCMD-RS and 1 RCMD) and a poor prognosis with a median survival of only 6 months for patients with del(17p) and 3 months in case of patients with CN-LOH17p (Figure 1c) .
The identification of several cases with overlapping CN-LOH17p led us to hypothesize that TP53 mutations would be present in these patients. Overall, 19 of 21 instances of LOH17p included the TP53 locus: 7 were CN-LOH and 12 were deletions ( Figure 1a) . DNA was available for 15 of 19 of these patients. We found homozygous TP53 mutations in five of six patients (83%) with somatic CN-LOH and hemizygous TP53 mutation in seven of nine patients (78%) with del(17p) (Figure 1d ). Of 12 TP53 mutations found, 11 (92%) were missense and located in the DNA-binding core domain (residues 102-292) of TP53 (four in exon 5: C141Y, V172F, C176Y, H179Q; two in exon 6: H193N, H193R; one in exon 7: R249G; and four in exon 8: V272L, V272M, 2R273H twice; Table 1 3 ). One homozygous frameshift/nonsense mutation was found in exon 9. Overall, TP53 mutations were found in 12 of 15 cases (80%) with LOH in the TP53 locus. To compare the rate of TP53 mutations in MDS/AML patients with and without chromosome 17 aberrations by either MC or SNP-A, we screened an additional 40 patients with MDS or AML. Five patients had a normal karyotype, 14 had a complex karyotype (9 of 14 with aberrations of chromosomes 5, 7, or both; and 5 of 14 without aberrations of 5 or 7), 7 had sole -7/7q-, 4 had sole 5q-and 10 had -5/5q-or -7/7q-with other abnormalities. We found only two heterozygous mutations (M237I, R248Q) in these patients; in both cases, the patients had a complex karyotype with -5/5q-and -7/7q-without LOH17p. Of interest, one of these patients transformed from aplastic anemia (AA) to AML. For this patient, we were able to partially reconstruct the time of mutation occurrence. Five months after diagnosis with AA, SNP-A detected a minor clone with monosomy 7. At this time there was no sign of TP53 mutation. Two years after AA diagnosis, the patient developed AML. At this time, analysis of bone marrow by MC and SNP-A showed a complex karyotype, and a heterozygous mutation of TP53 was found.
In our cohort of 379 patients, 11.6% of cases had a complex karyotype (in our study, complex karyotype was defined as three or more chromosomal aberrations) and, of these, 45% also had LOH17p. Only one patient without a complex karyotype had LOH17p. In cases with a complex karyotype and LOH17p, -5/5q-and/or -7/7q-, TP53 mutations were frequent (75%). TP53 mutations were much less frequent (2 of 40; 5%) in patients without aberrations of chromosome 17 by either MC or SNP-A (Figure 1d ). These results are concordant with previous report showing complete or partial loss of 17p in 4.3% of 1138 MDS/AML patients. In 69% of those patients, a TP53 mutation was found as compared with a frequency of TP53 mutation of 3.1% in patients without abnormalities of chromosome 17.
2
Our findings emphasize the validity of Knudson's classic twohit model of tumorigenesis in which tumor suppressor genes such as TP53 must undergo inactivation of both alleles to permit tumor formation. 4 In this context, we propose two mechanisms by which both TP53 alleles may be inactivated. In the case of deletion 17p, one allele becomes inactivated by mutation and the wild-type allele is lost through deletion. In patients with CN-LOH17p, one more step can be considered: reduplication of the mutated TP53 allele as a result of an attempt to correct for the lost chromosomal material. Indeed, this mechanism has been proposed to explain homozygous TP53 mutations in patients with apparently normal chromosomes 17 and two fluorescent in situ hybridization signals for TP53. 5 Our results suggest that intragenic TP53 mutation preceded LOH17p, based on the fact that we found two patients with heterozygous TP53 mutations without the presence of LOH17p by MC or SNP-A. It is likely that such patients would show disease progression associated with subsequent 17p deletion or somatic CN-LOH17p, either of which would lead to the loss of the protective wild-type allele.
A high frequency of TP53 mutations in at least a partially heterozygous constellation has been described in AML with a complex karyotype. 2, 6, 7 However, as neither SNP-A nor microsatellite analyses were carried out in these studies, we suggest an alternative explanation that identical findings could occur if DNA were isolated from a mixture of normal and abnormal cells, in which a clone of cells with CN-LOH17p is the source of the homozygous mutated allele and admixed normal cells are the source of the wild-type allele. We and others 2, 6, 7 have shown that TP53 mutations occur frequently in MDS/AML patients with complex karyotype, especially with del17p, del5/5q and del7/7q, and are very rare in patients with other cytogenetic abnormalities. Our results point towards the presence of homozygous mutations in the context of CN-LOH17p, whereas previous studies showed the presence Letters to the Editor of hemizygous mutations. Our study explains why in the former studies patients with del5/5q-and del7/7q-showed TP53 mutations without obvious del17p: they may have had CN-LOH17p. We have proceeded to sequence patients without del17 (with and without del5/5q and del7/7q) and found two mutations in 40 (5%) patients; in a previous study in which such patients were sequenced, only 8 of 256 (3.1%) mutations were found to be likely associated with CN-LOH17p for which they were not screened.
2 A high incidence of TP53 mutation in MDS/AML patients with complex cytogenetics with deletions of chromosomes 5, 7 and 17 suggests a cooperative effect between these lesions. This nonrandom pattern of DNA losses in MDS/AML patients with a complex karyotype is of interest, and suggests the presence of a multistep pathway, which is responsible for the sequential accumulation of certain chromosomal aberrations that results in poor clinical outcome. 8 In sum, our study shows that CN-LOH17p is a frequent type of cytogenetic defect occurring in patients with advanced MDS and secondary AML with a complex karyotype and is strongly associated with homozygous TP53 mutations. As described in previous reports, hemizygous deletions affecting this locus have been associated with mutation in the remaining TP53 allele. Previously, detection of TP53 mutations in patients without a visible cytogenetic deletion in this region prompted the assumption that these mutations were heterozygous.
2,6,7 However, our study indicates that in MDS/sAML, TP53 mutations can occur in either a hemizygous or homozygous constellation and heterozygous mutations are actually very rare as previously reported in a large cohort of patients.
2 Clinically, prognosis of patients with CN-LOH17p is as poor as that of patients with del17p. LOH17p is strongly associated with a complex karyotype in combination with whole or partial losses of chromosomes 5 and 7, and hemi-or homozygous TP53 mutations. Complex karyotypes with 5q and 7q abnormalities without del(17p) often harbor CN-LOH17p, a lesion which is cryptic unless analyzed by SNP-A. 1  del17p  8  273  CGT  CAT  R273H  S10  3%  4  del17p  6  193  CAT  AAT  H193N  L2  NA  6  del17p  7  249  AGG  GGG  R249G  L3  NA  7  del17p  5  179  CAT  CAG  H179Q  H1  NA  9  del17p  6  193  CAT  CGT  H193R  L2  0.6%  11  del17p  5  176  TGC  TAC  C176Y  L2  0.8%  13  del17p  8  273  CGT  CAT  R273H  S10  3%  14  CN-LOH17p  5  172  GTT  TTT  V172F  L2  NA The causes for stem cell resistance are unclear. In a recent study, primitive leukemic cells had higher BCR-ABL1 and CRKL kinase activity levels when compared with more mature cells. In addition, mRNA expression level of the imatinib uptake pump OCT-1 was lower and the drug efflux transporter protein ABCB1 (MDR) and ABCG2 levels were higher.
3
The stem cell persistence has also been implied in previous publications showing small numbers of Ph þ CD34 þ progenitor cells in bone marrow (BM) of CML patients even after years on TKI therapy. 4, 5 However, recent observations suggest that in a substantial proportion of CML patients who have reached complete molecular remission during TKI treatment, therapy can be discontinued without imminent relapse of the disease. A total of 25 chronic phase CML patients were included in the study; 17 patients were treated with imatinib (3 of them had discontinued treatment as per a study protocol), 5 with dasatinib, and 3 with bosutinib. The median time of TKI treatment was 21 months (range 3-72 months, Table 1 ). The study was conducted in accordance with the principles of the Helsinki declaration and was approved by the Helsinki University Central Hospital Ethics committee. Written informed consents were obtained from all patients as either part of clinical drug studies or separately.
Large volume (range 5-55 ml) BM aspirates were collected in EDTA anticoagulated tubes. The mononuclear cells were isolated with Ficoll (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) gradient centrifugation. CD34 þ cells were separated from mononuclear cell fraction with paramagnetic beads using AutoMACS separator (Miltenyi Biotech, Bergisch Gladbach, Germany). CD34 þ cells were stained with FITC-conjugated CD34 antibody and PE-conjugated CD38 antibody. Cells were sorted in three different fractions based on the expression of CD38 antigen: CD34 þ CD38 high , CD34 þ CD38 med , and CD34 þ CD38 neg (see Figure 1a) . The lowest 5% of cells were regarded CD38 negative. Cytospin slides were prepared from sorted cells (15 000-45 000 cells/slide).
From a proportion of samples additional staining was carried out with CD19, CD117, CD133, and CD13/33 antibodies to characterize the phenotype of different fractions.
All antibodies were purchased from BD Biosciences (San Jose, CA, USA). The FACS sorting and analysis were performed with FACSAria flowcytometer (BD).
Interphase FISH analysis was carried out on cytospin slides using locus-specific dual color, dual fusion BCR-ABL1 probe mixture (Vysis, Downers Crove, IL, USA) (Figures 1a and b) . Hybridizations were performed according to the manufacturer's instructions. Up to 1000 cells were aimed to be analyzed from every slide. The false positivity rate of the method is considered to be close to 0%. A highly sensitive metaphase fluorescence in situ hybridization (FISH) from a median of 1000 BM cells (instead of conventional G-banding of 20 metaphases) was used to define complete cytogenetic remission (CCyR). Molecular genetic analyses of BCR-ABL1 transcripts were carried out with standardized real-time quantitative PCR and the results were expressed on the international scale.
The median volume of collected BM aspirates was 30 ml (range 5-55 ml) with a median yield of 280 Â 10 6 mononuclear cells per sample. The median amount of CD34 þ CD38 neg cells obtained was 32 000 (range 1000-91 000) denoting that 1-3 cytospin slides of the most CD38-negative cell fraction were available for FISH analysis. The median number of interphase nuclei analyzed was 1005 with no difference in the different stem cells fractions (median number of 1004, 1002, and 1010 cells analyzed in CD34 þ CD38 high , CD34 þ CD38 med , and CD34 þ CD38 neg cell fractions, respectively). Although the analysis required large volume BM aspirates, it was feasible
